Clinical trial NCT00719745: A Study to Assess the Safety and Efficacy of Prograf and MR4 in Liver Transplant Recipients
Official title: A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf® (Tacrolimus) and MR4 (Modified Release Tacrolimus) in de Novo Liver Transplant Recipients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Liver Transplantation
Keywords: Organ transplantation
Tacrolimus
Prograf
MR4
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
Collaborators: name: Astellas Pharma Korea, Inc.
First posted: 2008-07-22
Enrollment: 74
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate and to compare efficacy and safety of MR4 versus Prograf in patients undergoing primary liver transplantation.


Eligibility criteria: Inclusion Criteria:

* Female patients of child bearing potential must have a negative in pregnancy test prior to enrollment and must agree to practice effective birth control during the study
* Patients who need liver transplantation due to the end-stage liver failure

Exclusion Criteria:

* Patients receiving multi-organ transplant or having previously received an organ transplant ( including re-transplantation)
* Patients receiving auxiliary graft or in whom a bio-artificial
* Patients allergic to macrolide antibiotics or tacrolimus
* Patients requiring immunosuppressive treatment or systemic chemotherapy prior to transplantation. Patients requiring low level immunosuppressive treatment ( MMF, steroids, azathioprine ) before transplantation to control their original liver disease can be included in the study, provided that this treatment is discontinued at the time of transplantation. Local chemotherapy is allowed
* Patients with malignancies of a history of malignancy within the last 5 years, with the exception of those with basalioma or squamous cell carcinoma of the skin that has been treated successfully Patients can be included under Milan Criteria Patients with malignancy which was identified after completion of surgery e.g. by histopathology will be allowed to remain in the study
* Patients with systemic infection requiring treatment, except viral hepatitis
* Patients with severe diarrhea, vomiting, active peptic ulcer or gastrointestinal disorder that may affect the absorption of tacrolimus
* Patients with serum creatinine \> 1.5mg/Dl
* Patients with any form of substance abuse, psychiatric disorder of condition which, in the opinion of the investigator, may complicate communication with the investigator
* Patients participating or participated in another clinical trial or those taking or having taken an investigational / non-registered drug in the past 28 days
* Patients who are pregnant or breast-feeding mother
* Patients or donors known to be HIV positive
* Patients unlikely to comply with the visits scheduled in the protocol

Primary outcomes:
measure: Event rate of patients with biopsy-proven acute rejections
timeFrame: 24 weeks
Secondary outcomes:
measure: Incidence of and time to acute rejections and corticosteroid resistant acute rejections
timeFrame: 12 and 24 weeks
measure: Severity of biopsy-proven acute rejections.
timeFrame: 24 weeks
measure: Patient and graft survival
timeFrame: 12 and 24 weeks
measure: Incidence of adverse events
timeFrame: Throughout trial
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
Study officials:
affiliation: Astellas Pharma Korea, Inc.
name: Central Contact
role: STUDY_CHAIR
References: